News in brief
Micelle specialist issues updated financials detailing losses
Nurish.me sells finished a line of finished products based largely on a micellular encapsulation technology developed by company founder and chief science officer Michal Hegar, PhD, during his work at the University of Utrecht in the Netherlands. The resulting ingredient, called CoreCumin, is a bioavailability-enhanced version of curcumin. The company sells a line of liquid products based on that ingredient.
As of May of this year, when Hegar spoke with NutraIngredients-USA, the company was also offering it as an ingredient to other companies. Nurish.me also sells a cognitive support finished product in powder form.
According to the new financial statements for fiscal 2017 and 2018, which were posted Sunday, Nurish.me had no revenue in 2017 and posted $73,516 in revenue in 2018. The company posed a net loss of $480,049 in 2017 and $968,259 in 2018.
"The continuing support of our shareholders and investors has allowed us to raise more than $3.4 million in equity and debt since May 2017, which has been partly utilized to develop clinically proven formulations that have been tested by five independent third-party analytical firms for their safety, purity, and integrity. In addition, funding was allocated to optimize our proprietary nanotechnology platform,” said CEO David Perez.
Nurish.me is a division of a company called Altavoz Entertainment. The stock trades in the penny realm at 50 cents a share.
